Synchrotron nanoscopy imaging study of scalp hair in breast cancer patients and healthy individuals: Difference in medulla loss and cortical membrane enhancements

2015 ◽  
Vol 79 (1) ◽  
pp. 23-30 ◽  
Author(s):  
Sung-Mi Han ◽  
Jun-Ichi Chikawa ◽  
Jae-Kun Jeon ◽  
Min-Young Hwang ◽  
Jun Lim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Scalp Hair ◽  
Imaging Study ◽  
Breast Cancer Patients ◽  
Healthy Individuals

scholarly journals Altered Impedance of Ear Acupuncture Point MT2 in Breast Cancer Patients: A Preliminary Observation

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Yine Hu ◽  
Huayuan Yang ◽  
Pin Wang ◽  
Tangyi Liu ◽  
Wenchao Tang
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Acupuncture Point ◽  
Preliminary Observation ◽  
Ear Acupuncture ◽  
Skin Impedance ◽  
Acupuncture Points ◽  
Breast Cancer Patients ◽  
Healthy Individuals ◽  
Healthy Humans

Skin impedance at acupuncture points (APs) has been used as a diagnostic aid for more than 50 years. In this study, we have a diagnostic tool (JXT-2008) to measure the skin impedance of ear APs of 30 breast cancer patients and the corresponding skin impedance of ear APs of 30 healthy humans, and then we compared these changes in ear AP impedance in breast cancer patients and healthy individuals.

scholarly journals Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients

2016 ◽  
Vol 62 (7) ◽  
pp. 1002-1011 ◽  
Author(s):  
Athina Markou ◽  
Martha Zavridou ◽  
Ioanna Sourvinou ◽  
George Yousef ◽  
Sofia Kounelis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Peripheral Blood ◽  
Breast Tumors ◽  
Breast Cancer Patients ◽  
Healthy Individuals ◽  
Primary Tumors ◽  
Expression Levels ◽  
Breast Tissues

Abstract BACKGROUND Circulating tumor cells (CTCs) and microRNAs (miRNAs) are important in liquid biopsies in which peripheral blood is used to characterize the evolution of solid tumors. We evaluated the expression levels of miR-21, miR-146a, miR-200c, and miR-210 in CTCs of breast cancer patients with verified metastasis and compared their expression levels in corresponding plasma and primary tumors. METHODS Expression levels of the miRNAs were quantified by quantitative reverse transcription PCR (RT-qPCR) in (a) 89 primary breast tumors and 30 noncancerous breast tissues and (b) CTCs and corresponding plasma of 55 patients with metastatic breast cancer and 20 healthy donors. For 30 of these patients, CTCs, corresponding plasma, and primary tumor tissues were available. RESULTS In formalin-fixed, paraffin-embedded tissues, these miRNAs were differentially expressed between primary breast tumors and noncancerous breast tissues. miR-21 (P < 0.001) and miR-146a (P = 0.001) were overexpressed, whereas miR-200c (P = 0.004) and miR-210 (P = 0.002) were underexpressed. In multivariate analysis, miR-146a overexpression was significantly [hazard ratio 2.969 (1.231–7.157), P = 0.015] associated with progression-free survival. In peripheral blood, all miRNAs studied were overexpressed in both CTC and corresponding plasma. There was a significant association between miR-21 expression levels in CTCs and plasma for 36 of 55 samples (P = 0.008). In plasma, ROC curve analysis revealed that miR-21, miR-146a, and miR-210 could discriminate patients from healthy individuals. CONCLUSIONS Metastasis-related miRNAs are overexpressed in CTCs and corresponding plasma; miR-21 expression levels highly correlate in CTCs and plasma; and miR-21, miR-146a, and miR-210 are valuable plasma biomarkers for discriminating patients from healthy individuals.

scholarly journals The Effects of Preoperative18F-FDG PET/CT in Breast Cancer Patients in Comparison to the Conventional Imaging Study

2012 ◽  
Vol 15 (4) ◽  
pp. 441 ◽  
Author(s):  
Young Jin Choi ◽  
Young Duck Shin ◽  
Yoon Hee Kang ◽  
Moon Soo Lee ◽  
Min Koo Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Fdg Pet ◽  
Imaging Study ◽  
Conventional Imaging ◽  
Breast Cancer Patients ◽  
Pet Ct ◽  
Fdg Pet Ct

MRI versus breast-specific gamma imaging (BSGI) in the detection of synchronous breast cancer: A prospective head-to-head trial.

2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 72-72
Author(s):  
L. J. Kirstein ◽  
J. L. Keto ◽  
D. P. Sanchez ◽  
T. Fulop ◽  
I. Cohen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Imaging Study ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Breast Cancers ◽  
Imaging Findings ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Significant Difference

72 Background: Literature suggests that MRI identifies additional mammographically and sonographically occult cancers in 8-10% of newly diagnosed breast cancer patients. We have reported comparable sensitivity of BSGI to MRI in the detection of the known index cancer. We sought to prospectively compare BSGI to MRI in the identification of additional occult malignancies in newly diagnosed breast cancer patients. Methods: Patients with newly diagnosed breast cancer from June 1, 2009 through February 4, 2011 were consented for an IRB approved protocol in which they underwent both breast MRI and BSGI. Each imaging study was read by a dedicated breast radiologist, with one reading all MRI, and another reading all BSGI studies. All subsequent biopsies were performed percutaneously under image guidance and reviewed by dedicated pathologists. The identification of additional occult breast cancers by MRI and BSGI was compared. Results: Eighty-five patients underwent both MRI and BSGI. Twenty-one patients elected to undergo mastectomy without further management of imaging findings and were excluded, leaving 64 eligible patients. No additional lesions were found in 22 patients. Twenty-one patients had benign pathology on biopsied imaging findings. Metastatic axillary lymph nodes, satellite lesions or larger extent of disease was identified in 11 patients. Eleven occult breast cancers were identified in 10 patients (15.6%), 6 on MRI alone (9.4%), 3 on BSGI alone (4.7%), and 2 by both modalities (3.1%). There was no significant difference in the identification of occult cancer between MRI and BSGI (chi-square 0.77, p>0.1; Table). Conclusions: BSGI has previously been shown to be as sensitive as MRI for detecting known invasive and in situ breast carcinoma. This study shows that BSGI is equally sensitive to MRI in the detection of synchronous mammographically and sonographically occult cancers in newly diagnosed breast cancer patients. Further research is needed to identify the false positive rates of BSGI and the effect on surgical management in comparison to MRI. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document